Cancer Screening and Prevention Research Group

Who we are

The Cancer Screening and Prevention Research Group (CSPRG) is an internationally renowned research group based at Imperial College London. Established in 2008 by the late Professor Wendy Atkin and now headed by Professor Amanda Cross, the group has extensive expertise in conducting clinical trials and includes an experienced team of research scientists, statisticians, clinical trial managers, data analysts and data managers.

What we do

The research focus of the Cancer Screening and Prevention Research Group (CSPRG) is bowel cancer, also known as colorectal cancer. In the UK, over 41,000 people are diagnosed with bowel cancer every year and 16,000 people die from the disease. Through our research we hope to reduce the numbers of people receiving a diagnosis of bowel cancer and dying from this disease. Much of our work focuses on how to help make bowel cancer screening programmes more effective and acceptable for participants, and more efficient for the NHS, and other health services internationally.

How we do it

We conduct large scale studies by either recruiting people from participating healthcare providers or by collating and analysing data collected from UK based hospitals and other data providers.

How we are funded

We receive funding from the UK Government, through the Department of Health and research councils, as well as charities including Cancer Research UK and the Bobby Moore Fund. The Faecal Immunochemical Tests (FIT) for the FIT for Follow-Up study were provided in kind by Eiken Chemical Co. Ltd and Mast Group Ltd. KeyMed Ltd provided funding in 1994 for a pilot study in preparation for the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Information we may hold about you and your options if you wish to opt out

If you have taken part in a bowel cancer screening programme, gone to your GP with symptoms suggestive of colorectal cancer, agreed to participate in one of our studies or had bowel cancer treatment on the NHS, we may retain some information about you. Our Patient Data page provides further details on how we process this data and your options if you wish to opt out.

For researchers – requesting data

Data used in CSPRG research was collected subject to the informed consent of the participants and / or under section 251 support. Access to the individual level anonymised data will only be granted in line with the relevant informed consent form or section 251 support, subject to approval by the appropriate research ethics committee, Health Research Authority (HRA) and HRA Confidentiality Advisory Group (HRA-CAG) as required, under a formal data sharing agreement.

To discuss a request for data please contact the CSPRG by completing the contact form with the following information: the proposed study objectives, the data you require and timelines for completion of the research.

Microbiome analysis shows potential to improve #bowelcancer #cancerscreening accuracy. 🔬🦠
Findings of OPTIMISTICC team funded by @CR_UK @CRUKresearch @theNCI @CancerGrand out now in @CCR_AACR

UK #cancer patients 1.5 times more likely to die than other European cancer patients following COVID-19. New findings from @ImperialBRC
study OnCovid led by @DJPinato @ImperialSandC published in EJC @OncologyAdvance ▶️!

We’re urging UK Government to invest in medical research charities. We support @AMRC calls to protect vital #ResearchAtRisk

2020 GLOBOCAN global #cancer statistics from @IARCWHO
#Colorectalcancer was the 3rd most diagnosed cancer (10%) and 2nd leading cause of cancer death (9.4%).

Make sure you submit your abstract for the BSG Annual Meeting Online for your chance to be to be published in @Gut_BMJ and to be included in the 2021 scientific programme! Submit your abstract by 1st June ⌛ #BSG2021

Load More...